General
Preferred name
TELBIVUDINE
Synonyms
NV 02B ()
L-Thymidine ()
Epavudine ()
1-[(2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-1,2,3,4-tetrahydropyrimidine-2,4-dione ()
2'-deoxy-l-thymidine ()
LDT-600 ()
Sebivo ()
Telbivudina ()
Tyzeka ()
NV-02B ()
LDT600 ()
P&D ID
PD009929
CAS
3424-98-4
Tags
available
drug
prodrug
Approved by
EMA
FDA
First approval
2006
Drug indication
Hepatitis B virus infection
Drug Status
approved
withdrawn
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PRICE 33
DESCRIPTION Telbivudine (NV 02B) is a Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor. The mechanism of action of telbivudine is as a Nucleoside Reverse Transcriptase Inhibitor. The chemical classification of telbivudine is Nucleoside Analog. (TargetMol Bioactive Compound Library)
Cell lines
0
Organisms
1
Compound Sets
16
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Enamine Bioactive Compounds
Enamine BioReference Compounds
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
VGSC-DB
External IDs
110
Properties
(calculated by RDKit )
Molecular Weight
242.09
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
3
Rotatable Bonds
2
Ring Count
2
Aromatic Ring Count
1
cLogP
-1.51
TPSA
104.55
Fraction CSP3
0.6
Chiral centers
3.0
Largest ring
6.0
QED
0.58
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
HBV
Protein P
Reverse Transcriptase
Indication
hepatitis B
MOA
DNA polymerase inhibitor
Therapeutic Class
Antiviral Agents
VGSC Target
Nav1.5
Pathway
Microbiology/virology
Source data